Roger Song
Stock Analyst at Jefferies
(4.23)
# 368
Out of 5,182 analysts
57
Total ratings
46.94%
Success rate
21.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Buy | $6 → $10 | $2.22 | +351.47% | 1 | Apr 15, 2026 | |
| REPL Replimune Group | Downgrades: Hold | $13 → $2 | $2.63 | -23.95% | 3 | Apr 13, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $8 → $16 | $4.17 | +283.69% | 4 | Mar 18, 2026 | |
| MANE Veradermics | Initiates: Buy | $75 | $99.33 | -24.49% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $17.90 | +246.37% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $270.72 | +37.04% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $98.53 | +19.76% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $15.61 | +169.06% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $84.24 | +43.64% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $75.38 | -40.30% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.66 | +108.88% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $432 → $564 | $566.90 | -0.51% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.61 | +211.53% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.79 | +2,045.65% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $30.11 | +19.56% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $53.00 | +1.89% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.42 | +324.03% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.31 | +111.48% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.32 | +255.19% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.88 | +215.32% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $4.27 | +64.13% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $67.85 | +31.17% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $7.99 | +213.09% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $17.28 | +137.27% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.92 | +95.31% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $58.97 | +118.76% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $102.08 | -4.98% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $33.18 | +231.53% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $2.76 | +1,168.12% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.24 | +112.26% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $35.76 | +487.25% | 1 | Sep 2, 2020 |
Allogene Therapeutics
Apr 15, 2026
Maintains: Buy
Price Target: $6 → $10
Current: $2.22
Upside: +351.47%
Replimune Group
Apr 13, 2026
Downgrades: Hold
Price Target: $13 → $2
Current: $2.63
Upside: -23.95%
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $8 → $16
Current: $4.17
Upside: +283.69%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $99.33
Upside: -24.49%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $17.90
Upside: +246.37%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $270.72
Upside: +37.04%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $98.53
Upside: +19.76%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $15.61
Upside: +169.06%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $84.24
Upside: +43.64%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $75.38
Upside: -40.30%
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.66
Upside: +108.88%
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $566.90
Upside: -0.51%
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.61
Upside: +211.53%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.79
Upside: +2,045.65%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $30.11
Upside: +19.56%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $53.00
Upside: +1.89%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.42
Upside: +324.03%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.31
Upside: +111.48%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.32
Upside: +255.19%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.88
Upside: +215.32%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $4.27
Upside: +64.13%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $67.85
Upside: +31.17%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $7.99
Upside: +213.09%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $17.28
Upside: +137.27%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $17.92
Upside: +95.31%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $58.97
Upside: +118.76%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $102.08
Upside: -4.98%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $33.18
Upside: +231.53%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $2.76
Upside: +1,168.12%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $4.24
Upside: +112.26%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $35.76
Upside: +487.25%